Skip to main content
Quest Diagnostics

Analytical Validation and Performance Characteristics of a 523-Gene Next-Generation Sequencing Panel for Comprehensive Genomic Profiling in Solid Tumors

AMP 2023

Association for Molecular Pathology

Salt Lake City, UT, Nov 14-18 2023

Poster presentation: Analytical Validation and Performance Characteristics of a 523-Gene Next-Generation Sequencing Panel for Comprehensive Genomic Profiling in Solid Tumors

Authors: Acab A, Neishaboori N, Ma C, Gonong B,Toliver V, Racke F, Godsey J

Specialty: Oncology

Related conttent

Publication
Sporadic Oncocytic Tumors with Features Intermediate between Oncocytoma and Chromophobe
Validation and adoption of an IGVH mutational status assay in chronic lymphocytic leukemia (CLL) using next-generation sequencing (NGS) in a clinical laboratory
Conference Presentation
Highly specific copy number variant flagging algorithm using next generation sequencing in cancer predisposition genes
Publication
Target Enrichment Approaches for Next-Generation Sequencing Applications in Oncology
Audio Podcast
Optimize Oncology Care with Clinical Pathways
Test FAQ
Solid Tumor Core Panel
Test FAQ
Solid Tumor Expanded Panel

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2025 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.